![Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1](/images/research/ff6e6cbe-cb9c-4d11-87ef-671d28ffd4fa/small/15506.jpg)
research Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1
Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
Search
for
Sort by
Research
300-330 / 1000+ results research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate Cancer
New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.
research Desenvolvimento e caracterização de nanopartículas poliméricas carregadas com fosfato de clindamicina para tratamento tópico da acne vulgar
NP-AH-CDM-4 nanoparticles show promise for effective topical acne treatment.
research Abstracts
Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
research Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.
research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study
The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Topical immunotherapy in alopecia areata
Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Teicoplanin alleviates androgenetic alopecia through inhibition of androgen receptor expression and enhancing dermal papilla cell proliferation
Teicoplanin may help treat hair loss by reducing androgen receptors and boosting hair cell growth.
research Exploring the Mechanism of Platycladi Cacumen in Intervening Androgenetic Alopecia Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation
Platycladi Cacumen may help treat hair loss by targeting specific proteins and pathways.
research 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
research Central centrifugal cicatricial alopecia: a subtype of lichen planopilaris in African descent?
CCCA and LPP may be related hair loss conditions influenced by genetics and environment, needing early treatment.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Simple and Selective HPLC-UV/Vis Bioanalytical Method to Determine Aluminum Phthalocyanine Chloride in Skin Permeation Studies
A new method accurately measures a drug in skin for cancer therapy research.
research Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins
Combining finasteride with dimethyl-β-cyclodextrin improves its absorption and bioavailability.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research SnapshotDx Quiz: May 2020
BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research Drug-induced alopecia after dupilumab therapy
Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
research [Finasteride--ris of "unintentional doping"].
research Unlocking finasteride's potential via carboxymethyl-β-cyclodextrin inclusion complex for androgenic alopecia
The new method improves finasteride's effectiveness for hair loss treatment.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.